BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio?

Key Takeaways BMY will co-develop BioNTech's BNT327, targeting PD-L1 and VEGF-A in multiple solid tumor types The billion-dollar deal includes an upfront payment of $1.5 billion, along with other payments BMY seeks pipeline growth as drugs like Revlimid and Abraxane lose ground to genericsBristol Myers Squibb (BMY) recently announced a strategic collaboration agreement with BioNTech (BNTX) for the global co-development and co-commercialization of the latter’s investigational bispecific antibody BNT327 acr ...